CompletedNot Applicable

Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?

United Kingdom203 participantsStarted 2015-01

Plain-language summary

This study evaluates whether patients with Clostridium difficile infection (CDI) who are treated with fidaxomicin have less contamination of their skin and surrounding environment with spores of C. difficile than patients treated with other drugs (metronidazole or vancomycin)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of CDI (see above) * Prescribed fidaxomicin, vancomycin or metronidazole by attending physician Exclusion Criteria: * Patients whose clinical care team indicates it would be inappropriate to include him/her in the study (e.g. due to terminal illness) * In a patient receiving metronidazole or vancomycin, receipt of fidaxomicin within the previous 3 months * patients unable to give informed consent for whom no consultee is available to give approval * non-English speakers

What they're measuring

The presence of environmental contamination with C. difficile spores during and following treatment with fidaxomicin, vancomycin or metronidazole.

Timeframe: Up to 28 days after treatment

The presence of skin contamination with C. difficile spores during and following treatment with fidaxomicin, vancomycin or metronidazole.

Timeframe: Up to 28 days after treatment

Trial details

NCT IDNCT02461901

SponsorProfessor Mark Wilcox

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-12-31

View on ClinicalTrials.gov More Clostridium Difficile Infection trials